Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Breast Cancer | Research

The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining

Authors: Dong Xu, Yiqi Zhang, Feng Jin

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Tamoxifen (TAM) resistance to invasive lobular cell carcinoma is a challenge for breast cancer treatment. This study explored the role of Aldo-keto reductase family 1 (AKR1) family in tamoxifen-resistant aggressive lobular breast cancer based on data mining.

Methods

TAM-resistant invasive lobular breast cancer gene chip was downloaded from the Gene Expression Omnibus (GEO) database (accession-numbered as GSE96670). The online analytical tool GEO2R was used to screen for differentially expressed genes in TAM-resistant invasive lobular breast cancer cells and TAM-sensitive counterparts. A protein-protein interaction (PPI) networks were constructed using the STRING online platform and the Cytoscape software. GeneMANIA and GSCALite online tools were used to reveal the potential role of these hub genes in breast cancer progression and TAM resistance development. And the used the GSE67916 microarray data set to verify the differentially expression of these hub genes in breast cancer. The protein expression levels of AKR1C1, AKR1C2 and AKR1C3 in TAM-sensitive and resistant breast cancer cells were compared. The TAM sensitivity of breast cancer cells with or without AKR1C1, AKR1C2 or AKR1C3 gene manipulation was evaluated by cell viability assay.

Results

A total of 184 differentially expressed genes were screened. Compared with TAM sensitive breast cancer cells, 162 were up-regulated and 22 were down-regulated. The study identified several hub genes in the PPI network that may be involved in the development of TAM resistance of breast cancer, including signal transducer and activator of transcription 1 (STAT1), estrogen receptor alpha (ESR1), fibronectin1 (FN1), cytochrome P4501B1 (CYP1B1), AKR1C1, AKR1C2, AKR1C3 and uridine diphosphate glucuronosyltransferase (UGT) 1A family genes (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10). Compared with TAM-sensitive counterparts, the expression levels of AKR1C1, AKR1C2, and AKR1C3 were up-regulated in TAM-resistant breast cancer cells.

Conclusions

Overexpression of each of these three genes significantly increased the resistance of breast cancer cells to TAM treatment, while their knockdown showed opposite effects, indicating that they are potential therapeutic target for the treatment of TAM-resistant breast cancer.

Available only for authorised users

Wieder R, Shafiq B, Adam N. Greater survival improvement in african american vs. caucasian women with hormone negative breast cancer. J Cancer. 2020;11(10):2808–20. https://doi.org/10.7150/jca.39091.CrossRefPubMedPubMedCentral

Engstrøm MJ, Opdahl S, Vatten LJ, Haugen OA, Bofin AM. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes. Histopathology. 2015;66(3):409–19. https://doi.org/10.1111/his.12572.CrossRefPubMed

Chen Z, Yang J, Li S, Lv M, Shen Y, Wang B, et al. Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS One. 2017;12(9):e0182397. https://doi.org/10.1371/journal.pone.0182397.CrossRefPubMedPubMedCentral

Dania V, Liu Y, Ademuyiwa F, Weber JD, Colditz GA. Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ. Breast Cancer Res. 2019;21(1):120. https://doi.org/10.1186/s13058-019-1219-8.CrossRefPubMedPubMedCentral

Kim YG, Park YH, Yang EY, Park WS, Park KS. Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines. Ann Surg Treat Res. 2019;97(5):230–8. https://doi.org/10.4174/astr.2019.97.5.230.CrossRefPubMedPubMedCentral

Piva M, Domenici G, Iriondo O, Rábano M, Simões BM, Comaills V, et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med. 2014;6(1):66–79. https://doi.org/10.1002/emmm.201303411.CrossRefPubMed

Sanchez-Spitman AB, Moes DA, Gelderblom H, Dezentjé VO, Swen JJ, Guchelaar HJ. The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. Pharmacogenomics. 2017;18(12):1125–32. https://doi.org/10.2217/pgs-2017-0080.CrossRefPubMed

Wang Q, Gun M, Hong XY. Induced tamoxifen resistance is mediated by increased methylation of e-cadherin in estrogen receptor-expressing breast cancer cells. Sci Rep. 2019;9(1):14140. https://doi.org/10.1038/s41598-019-50749-1.CrossRefPubMedPubMedCentral

Ye L, Lin C, Wang X, Li Q, Li Y, Wang M, et al. Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. EMBO Mol Med. 2019;11(12):e10638. https://doi.org/10.15252/emmm.201910638.CrossRefPubMedPubMedCentral

10.

Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7. https://doi.org/10.1038/nature11252.

11.

Dong P, Yu B, Pan L, Tian X, Liu F. Identification of key genes and pathways in triple-negative breast Cancer by integrated bioinformatics analysis. Biomed Res Int. 2018;2018:2760918. https://doi.org/10.1155/2018/2760918.CrossRefPubMedPubMedCentral

12.

Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214–20. https://doi.org/10.1093/nar/gkq537.CrossRefPubMedPubMedCentral

13.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–d13. https://doi.org/10.1093/nar/gky1131.CrossRef

14.

Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res. 2019;18(2):623–32. https://doi.org/10.1021/acs.jproteome.8b00702.CrossRefPubMed

15.

Shen S, Kong J, Qiu Y, Yang X, Wang W, Yan L. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis. J Cell Biochem. 2019;120(6):10069–81. https://doi.org/10.1002/jcb.28290.CrossRefPubMed

16.

Kim EK, Song MJ, Jung Y, Lee WS, Jang HH. Proteomic Analysis of Primary Colon Cancer and Synchronous Solitary Liver Metastasis. Cancer Genomics Proteomics. 2019;16(6):583–92. https://doi.org/10.21873/cgp.20161.CrossRefPubMedPubMedCentral

17.

Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771–2. https://doi.org/10.1093/bioinformatics/bty411.CrossRefPubMed

18.

Fu X, Liu M, Qu S, Ma J, Zhang Y, Shi T, et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 2018;37(1):52. https://doi.org/10.1186/s13046-018-0677-7.CrossRefPubMedPubMedCentral

19.

Zheng W, Duan B, Zhang Q, Ouyang L, Peng W, Qian F, et al. Vitamin D-induced vitamin D receptor expression induces tamoxifen sensitivity in MCF-7 stem cells via suppression of Wnt/β-catenin signaling. Biosci Rep. 2018;38(6). https://doi.org/10.1042/BSR20180595.

20.

Hammad S, Othman A, Meyer C, Telfah A, Lambert J, Dewidar B, et al. Confounding influence of tamoxifen in mouse models of Cre recombinase-induced gene activity or modulation. Arch Toxicol. 2018;92(8):2549–61. https://doi.org/10.1007/s00204-018-2254-4.CrossRefPubMed

21.

Ahn SH, Granger A, Rankin MM, Lam CJ, Cox AR, Kushner JA. Tamoxifen suppresses pancreatic β-cell proliferation in mice. PLoS One. 2019;14(9):e0214829. https://doi.org/10.1371/journal.pone.0214829.CrossRefPubMedPubMedCentral

22.

Zhou WB, Zhang XX, Cai Y, Sun W, Li H. Osthole prevents tamoxifen-induced liver injury in mice. Acta Pharmacol Sin. 2019;40(5):608–19. https://doi.org/10.1038/s41401-018-0171-y.CrossRefPubMed

23.

Varikuti S, Oghumu S, Elbaz M, Volpedo G, Ahirwar DK, Alarcon PC, et al. STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade. Oncoimmunology. 2017;6(11):e1361088. https://doi.org/10.1080/2162402X.2017.1361088.CrossRefPubMedPubMedCentral

24.

Nam YS, Im KI, Kim N, Song Y, Lee JS, Jeon YW, et al. Down-regulation of intracellular reactive oxygen species attenuates P-glycoprotein-associated chemoresistance in Epstein-Barr virus-positive NK/T-cell lymphoma. Am J Transl Res. 2019;11(3):1359–73.PubMedPubMedCentral

25.

Hou Y, Li X, Li Q, Xu J, Yang H, Xue M, et al. STAT1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferation. J Cell Mol Med. 2018;22(12):6077–86. https://doi.org/10.1111/jcmm.13882.CrossRefPubMedPubMedCentral

26.

Kim S, Lee J, Lee SK, Bae SY, Kim J, Kim M, et al. Protein kinase C-α downregulates estrogen receptor-α by suppressing c-Jun phosphorylation in estrogen receptor-positive breast cancer cells. Oncol Rep. 2014;31(3):1423–8. https://doi.org/10.3892/or.2013.2936.CrossRefPubMed

27.

Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, et al. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016;157(2):253–65. https://doi.org/10.1007/s10549-016-3829-5.CrossRefPubMedPubMedCentral

28.

Li C, Wang Z, Wang Q, Ka Yan Ho RL, Huang Y, Chow MSS, et al. Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model. Oncotarget. 2018;9(3):3338–52. https://doi.org/10.18632/oncotarget.23235.CrossRefPubMed

29.

Lanxiang W, Bin W, Ge X, Yutang H, Chunjie W, Honghao Z. Long-term exposure of 4-hydroxyestradiol induces the cancer cell characteristics via upregulating CYP1B1 in MCF-10A cells. Toxicol Mech Methods. 2019;29(9):686–92. https://doi.org/10.1080/15376516.2019.1650146.CrossRefPubMed

30.

Yang X, Hu Q, Hu LX, Lin XR, Liu JQ, Lin X, et al. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. Discov Med. 2017;24(131):75–85.PubMed

31.

Huang R, Faratian D, Sims AH, Wilson D, Thomas JS, Harrison DJ, et al. Increased STAT1 signaling in endocrine-resistant breast cancer. PLoS One. 2014;9(4):e94226. https://doi.org/10.1371/journal.pone.0094226.CrossRefPubMedPubMedCentral

32.

de Almagro MC, Selga E, Thibaut R, Porte C, Noé V, Ciudad CJ. UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate. Biochem Pharmacol. 2011;81(1):60–70. https://doi.org/10.1016/j.bcp.2010.09.008.CrossRefPubMed

33.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20(7):1757–67. https://doi.org/10.1158/1078-0432.CCR-13-2332.CrossRefPubMedPubMedCentral

34.

Rangel N, Rondon-Lagos M, Annaratone L, Osella-Abate S, Metovic J, Mano MP, et al. The role of the AR/ER ratio in ER-positive breast cancer patients. Endocr Relat Cancer. 2018;25(3):163–72. https://doi.org/10.1530/ERC-17-0417.CrossRefPubMed

35.

Bronte G, Rocca A, Ravaioli S, Puccetti M, Tumedei MM, Scarpi E, et al. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? BMC Cancer. 2018;18(1):348. https://doi.org/10.1186/s12885-018-4239-3.CrossRefPubMedPubMedCentral

36.

Ide H, Lu Y, Noguchi T, Muto S, Okada H, Kawato S, et al. Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer. Cancer Sci. 2018;109(4):1230–8. https://doi.org/10.1111/cas.13517.CrossRefPubMedPubMedCentral

37.

Pippione AC, Giraudo A, Bonanni D, Carnovale IM, Marini E, Cena C, et al. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach. Eur J Med Chem. 2017;139:936–46. https://doi.org/10.1016/j.ejmech.2017.08.046.CrossRefPubMed

38.

Hara A, Endo S, Matsunaga T, Soda M, Yashiro K, El-Kabbani O. Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily. J Biochem. 2017;162(5):371–9. https://doi.org/10.1093/jb/mvx041.CrossRefPubMed

39.

Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, Gras T, et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia. 2010;12(9):727–39. https://doi.org/10.1593/neo.10526.CrossRefPubMedPubMedCentral

Title: The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining
Authors: Dong Xu
Yiqi Zhang
Feng Jin
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Tamoxifen
Estrogens
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-09040-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy

Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy

Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study

Identification of key pseudogenes in nasopharyngeal carcinoma based on RNA-Seq analysis

Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA)

A novel nomogram containing acute radiation esophagitis predicting radiation pneumonitis in thoracic cancer receiving radiotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer